Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.56 |
| ▸ | PDE5A | O76074 | 6/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.54 |
| ▸ | MIF | P14174 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194316 | 0.84 | PDE4B (0.52) | PDE4BPDE5AMAPK14ADORA2AADORA1 | |
| SCHEMBL3201178 | 0.84 | PDE4B (0.54) | PDE4BPDE5AMAPK14ADORA2AADORA1 | |
| SCHEMBL12897932 | 0.82 | PDE4B (0.50) | PDE4BPDE5AMAPK14ADORA2AADORA1 | |
| SCHEMBL1268920 | 0.81 | PDE4B (0.49) | PDE4BPDE5AMAPK14ADORA2AADORA1 | |
| SCHEMBL1270088 | 0.79 | PDE4B (0.47) | PDE4BPDE5AMAPK14ADORA2AADORA1 | |
| SCHEMBL3197217 | 0.78 | PDE4B (0.52) | PDE4BPDE5AADORA2AADORA1PDE3A | |
| SCHEMBL1269980 | 0.78 | PDE4B (0.52) | PDE4BPDE5AMAPK14ADORA2AADORA1 | |
| SCHEMBL3195918 | 0.78 | PDE4B (0.52) | PDE4BPDE5AMAPK14ADORA2AADORA1 | |
| SCHEMBL1270275 | 0.78 | PDE4B (0.46) | PDE4BPDE5AMAPK14ADORA2AADORA1 | |
| SCHEMBL4359398 | 0.77 | PDE4B (0.51) | PDE4BPDE5AMAPK14ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2010-02-11 | — | — | US | claimed |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | MEDICINOVA, INC. | 2009-12-24 | — | — | US | claimed |
| EP-2038279-A2 | SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | Avigen, Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2007146087-A2 | SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | MEDICINOVA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | MEDICINOVA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | MEDICINOVA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-2038279-A2 | SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | Avigen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2007146087-A2 | SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | PNPO, PDXK, CYP3A5 | PDE4B 383/4885PDE5A 418/4885MAPK14 1459/4885 |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | PNPO, PDXK, P2RX5 | PDE4B 351/4885PDE5A 413/4885MAPK14 1712/4885 |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | PNPO, PDXK, CYP3A5 | PDE4B 383/4885PDE5A 418/4885MAPK14 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.